Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection : A TBnet and ESGMYC study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
The Journal of infection - 84(2022), 6 vom: 25. Juni, Seite 834-872 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tunesi, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.05.2022 Date Revised 06.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2022.03.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338027688 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338027688 | ||
| 003 | DE-627 | ||
| 005 | 20231225235739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2022.03.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM338027688 | ||
| 035 | |a (NLM)35271917 | ||
| 035 | |a (PII)S0163-4453(22)00130-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tunesi, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection |b A TBnet and ESGMYC study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2022 | ||
| 500 | |a Date Revised 06.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 700 | 1 | |a Dû, Damien Le |e verfasserin |4 aut | |
| 700 | 1 | |a Gualano, Gina |e verfasserin |4 aut | |
| 700 | 1 | |a Millet, Joan-Pau |e verfasserin |4 aut | |
| 700 | 1 | |a Skrahin, Aliaksandr |e verfasserin |4 aut | |
| 700 | 1 | |a Bothamley, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Casas, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Musso, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Pourcher, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Rioux, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Skrahina, Alena |e verfasserin |4 aut | |
| 700 | 1 | |a Veziris, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Viatushka, Dzmitry |e verfasserin |4 aut | |
| 700 | 1 | |a Jachym-Fréchet, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Guglielmetti, Lorenzo |e verfasserin |4 aut | |
| 700 | 0 | |a TBnet, The ESGMYC, and The French MDR-TB Group |e verfasserin |4 aut | |
| 700 | 1 | |a Marigot-Outtandy, Dhiba |e investigator |4 oth | |
| 700 | 1 | |a Lescure, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Dubert, Marie |e investigator |4 oth | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e investigator |4 oth | |
| 700 | 1 | |a Caumes, Eric |e investigator |4 oth | |
| 700 | 1 | |a Choinier, Pascaline |e investigator |4 oth | |
| 700 | 1 | |a Haddad, Elie |e investigator |4 oth | |
| 700 | 1 | |a Kowalczyk, Jakub |e investigator |4 oth | |
| 700 | 1 | |a Laurichesse, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Lesens, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Aubry, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Bonnet, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Morel, Florence |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 84(2022), 6 vom: 25. Juni, Seite 834-872 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2022 |g number:6 |g day:25 |g month:06 |g pages:834-872 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2022.03.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2022 |e 6 |b 25 |c 06 |h 834-872 | ||